Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Jang, Ji Young ^a   Lee, Jong Kuen ^a   Jeon, Yoon Kyung ^a   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

EGCG; Exosomes; miR 16; Tumor microenvironment; Tumor associated macrophages (TAM)

Indexed keywords

COLONY STIMULATING FACTOR 1; EPIGALLOCATECHIN GALLATE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MICRORNA 16; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; EX VIVO STUDY; EXOSOME; GENE SILENCING; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; EXOSOMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICRORNAS; PARACRINE COMMUNICATION;

EID: 84883887202     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-421     Document Type: Article

References (48)

1. Gezgen G, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Metabolic syndrome and breast cancer: an overview. J Buon 2012, 17:223-229.
2. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA Cancer J Clin 1991, 41:146-165.
3. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr 2004, 7:187-200.
4. Yang CS, Sang S, Lambert JD, Hou Z, Ju J, Lu G. Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res 2006, 50:170-175.
5. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000, 71:1698S-1702S.
6. Lambert JD, Hong J, Yang GY, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005, 81:284S-291S.
7. Stuart EC, Scandlyn MJ, Rosengren RJ. Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 2006, 2006(79):2329-2336.
8. Zhang G, Miura Y, Yagasaki K. Effects of green, oolong and black teas and related components on the proliferation and invasion of hepatoma cells in culture. Cytotechnology 1999, 31:37-44.
9. Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res 2006, 66:11494-11501.
10. Lu YP, Lou YR, Xie JG, et al. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci U S A 2002, 99:12455-12460.
11. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007, 245:232-241.
12. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004, 64:8715-8722.
13. Wang ZY, Huang MT, Ho CT, et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1999, 52:6657-6665.
14. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alphagranules. Blood 1999, 94:3791-3799.
15. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and megakaryocytederived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003, 17:33-42.
16. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001, 97:3075-3085.
17. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
18. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008, 15:80-88.
19. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005, 4:1595-1604.
20. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9:349-357.
21. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res 2011, 1:98-110.
22. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84:623-630.
23. Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
24. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:177-189.
25. Antonio S, Tiziana S, Alberto M, Paola A. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006, 42:717-727.
26. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006, 66:11432-11440.
27. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16:S27-S33.
28. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
29. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical NF-κB pathway by regulating IKKα expression during macrophage differentiation. Nat Immunol 2010, 11:799-805.
30. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. Re-educating tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205:1261-1268.
31. Shih JY, Jeremy AY, Chen JW, Yang PC. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2006, 2:101-106.
32. Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracellular Vesicles 2012, 1:18397.
33. Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012, 2012:1-10.
34. Théry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biology Reports 2011, 3:15.
35. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010, 78:838-848.
36. Rustom A, Saffrich R, Markovic I, et al. Nanotubular highways for intercellular organelle transport. Science 2004, 303:1007-1010.
37. Sherer NM, Mothes W. Cytonemes and tunnelling nanotubules in cell-cell communication and viral pathogenesis. Trends Cell Biol 2008, 18:414-420.
38. Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20:1487-1495.
39. Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 2011, 91:119-149.
40. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
41. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA?. RNA 2005, 11:1753-1761.
42. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM. Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5:e13515.
43. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 2008, 36:5391-5404.
44. Ofir M, Hacohen D, Ginsberg D. miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 2011, 9:440-447.
45. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
46. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010, 18:181-187.
47. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, Lu X. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010, 70:7176-7186.
48. Thorsten H, Subhra KB, Toby L, Antonio S, Claire EL. Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood 2009, 113:3139-3146.